Antisense gene therapy using anti-k-ras and antitelomerase oligonucleotides in colorectal cancer;Eficacia de la terapia génica antisentido utilizando oligonucleótidos anti K-ras y antitelomerasa en cancer colorrectal

Revista Espanola de Enfermedades Digestivas

Volumn 97, Issue 7, 2005, Pages 472-480

  Lledó, Salvador ^a,c   Alfonso, R ^a,c   Alino S F ^b  

^a Hospital Cliacute nico Universitario   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Antisense therapy; Colorectal cancer; K ras oncogene; Oligoribonucleotides; Telomerase

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; AS KRAS; ISIS 6957; K RAS PROTEIN; TELOMERASE; TELP5; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GENE THERAPY; HUMAN; HUMAN CELL;

EID: 26944490274     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082005000700002     Document Type: Article

References (24)

1. Hermanek P, Wiebelt H, Staimmer D, Riedl S. Prognostic factors of rectum carcinoma. Experience of the German Multicentre Study SGCRC. German Study Group Colo-Rectal Carcinoma. Tumori 1995; 81 (Supl. 3): 60-4.
2. Hermanek P. Impact of surgeon's technique on outcome after treatment of rectal carcinoma. Dis Colon Rectum 1999; 42 (5): 559-62.
3. Umpleby HC, Fermor B, Symes MO, Williamson RC. Viability of exfoliated colorectal carcinoma cells. Br J Surg 1984; 71 (9): 659-63.
4. Solomon MJ, Egan M, Roberts RA, Philips J, Russell P. Incidence free colorectal cancer cells on the peritoneal surface. Dis Colon Rectum 1997; 40 (11): 1294-8.
5. Ward RL, Todd AV, Santiago F, O'Connor T, Hawkins NJ. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer 1997; 79 (6): 1106-13.
6. Sakakura C, Hagiwara A, Tsujimoto H, Ozaki K, Sakakibara T, Oyama T, et al. Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger ARN of the Ki-ras gene. Anticancer Drugs 1995; 6 (4): 553-61.
7. Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 1998; 95 (7): 3609-14.
8. Dasí F, Marugán M, Lledó S, Cervantes A, García-Granero E, García-Conde J, et al. Telomerasa: biología e implicaciones clínicas. Hematol Citocinas Inmunoter Ter Cel 2002; 5 (2): 121-35.
9. Yoshida K, Sugino T, Goodison S, Warren BF, Nolan D, Wadsworth S, et al. Detection of telomerase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br J Cancer 1997; 75 (4): 548-53.
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266 (5193): 2011-5.
11. Brown T, Aldous W, Lance R, Blaser J, Baker T, Williard W. The association between telomerase, p53, and clinical staging in colorectal cancer. Am J Surg 1998; 175 (5): 364-6.
12. Mercola D, Cohen JS. Antisense approaches to cancer gene therapy. Cancer Gene Ther 1995; 2 (1): 47-59.
13. Andreyev HJN, Ross PJ, Cunningham D, Clarke PA. Antisense treatment directed against mutated ki-ras in human colorectal carcinoma. Gut 2001; 48 (2): 230-7.
14. Chen G, Oh S, Monia BP, Stacey DW. Antisense oligonucleotides demonstrate a dominant role of c-ki-ras proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 1996; 271 (45): 28259-65.
15. Pang JX, Chen XY, Xu W, Wu SG. Antisense Sp1 oligodeoxynucleotide decreases telomerase activity by inhibiting hTERT mRNA expression in Jurkat T cells. Acta Pharmacol Sin 2003; 24 (1): 91-6.
16. Pruzan R, Pongracz K, Gietzen K, Wallweber G, Gryaznov S. Allosteric inhibitors of telomerase: oligonucleotide N3′a P 5′phosphoramidates. Nucleic Acids Res 2002; 30 (2): 559-68.
17. Ross PJ, George M, Cunningham D, DiStefano F, Jervoise H, Andreyev H, et al. Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected kirsten-ras antisense oligonucleotides. Mol Cancer Ther 2001; 1 (1): 29-41.
18. Pang JX, Chen XY, Wu SG. Regulation of telomerase activity in Jurkat T cells by transcription factors Sp1 and Sp3. Di Yi Jun Yi Da Xue Xue Bao 2002; 22 (6): 481-5.
19. He DM, Zhang H. Telomerase gene antisense oligodoxynucleotide down-regulates telomerase activity in HL-60 cells. Ai Zheng 2002; 21 (10): 1070-4.
20. Wang X, Zhang Z, Xu Y, Chen S, Xiong W. Inhibition of telomerase activity and induction of apoptosis in lung cancer cell by human telomerase reverse transcriptase gene antisense oligodeoxynucleotide. Zhonghua Nei Ke Za Zhi 2002; 41 (3): 175-8.
21. Xie W, Lin M. Study on induction of leukemic cell apoptosis by antisense oligodeoxynucleotide of human telomerase RNA. Zhonghua Xue Ye Za Zhi 2001; 22 (5): 245-8.
22. Herbert BS, Pongracz K, Shay JW, Gryaznov SM, Shea-Herbert Brittney. Oligonucleotide N3′→P5′phosphoramidates as efficient telomerase inhibitors. Oncogene 2002; 21 (4): 638-42.
23. Elayadi AN, Demieville A, Wancewicz EV, Monia BP, Corey DR, Inhibition of telomerase by 2′-O- (2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. Nucleic Acids Res 2001; 29 (8): 1683-9.
24. Wong SC, Yu H, Moochhala SM, So JB. Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells. Anticancer Res 2003; 23 (1 A): 465-9.